BACKGROUND: Multidrug resistance protein 4 (MRP4) functions as an efflux pump of nucleoside monophosphate analogs, such as 6-mercaptopurine (6-MP) and 6-thioguanine nucleotide (6-TGN). A single-nucleotide polymorphism in human MRP4 (rs3765534) dramatically reduces MRP4 function and results in the intracellular accumulation of 6-TGN. In this study, we investigated the association between MRP4 G2269A polymorphism and thiopurine sensitivity in Japanese IBD patients. METHODS: Direct sequencing of the MRP4 exon 18 was performed. The TPMT A719G and ITPase C94A polymorphisms were determined by polymerase-chain reaction-restriction fragment length polymorphism analyses. RESULTS: Of the 279 samples analyzed (44 healthy volunteers and 235 IBD patients), 68 samples showed a heterozygote of MRP4 G2269A and 7 carried a homozygote. The allelic frequency of MRP4 G2269A was 14.7%. In 130 IBD patients treated with azathioprine/6-MP, the white blood cell count was significantly lower in patients with theMRP4 variant alone (n = 26) than in patients with a wild allelotype (n = 74) (P = 0.014) or in patients with the ITPase variant alone (n = 22) (P = 0.0095). The 6-TGN levels were significantly higher in patients with the MRP4 variant alone than in patients with the wild allelotype(P = 0.049). Of the 15 patients who experienced leucopenia (<3 x 10⁹/l), 7 patients carried the MRP4 variant.The odds ratio of carrying the MRP4 variant alone and having leukopenia was 3.30 (95% confidence interval 1.03–10.57, P = 0.036). CONCLUSIONS: These results suggest that MRP4 G2269A might be a new factor accounting for thiopurine sensitivity in Japanese patients with IBD.
BACKGROUND:Multidrug resistance protein 4 (MRP4) functions as an efflux pump of nucleoside monophosphate analogs, such as 6-mercaptopurine (6-MP) and 6-thioguanine nucleotide (6-TGN). A single-nucleotide polymorphism in humanMRP4 (rs3765534) dramatically reduces MRP4 function and results in the intracellular accumulation of 6-TGN. In this study, we investigated the association between MRP4 G2269A polymorphism and thiopurine sensitivity in Japanese IBDpatients. METHODS: Direct sequencing of the MRP4 exon 18 was performed. The TPMTA719G and ITPase C94A polymorphisms were determined by polymerase-chain reaction-restriction fragment length polymorphism analyses. RESULTS: Of the 279 samples analyzed (44 healthy volunteers and 235 IBDpatients), 68 samples showed a heterozygote of MRP4 G2269A and 7 carried a homozygote. The allelic frequency of MRP4 G2269A was 14.7%. In 130 IBDpatients treated with azathioprine/6-MP, the white blood cell count was significantly lower in patients with theMRP4 variant alone (n = 26) than in patients with a wild allelotype (n = 74) (P = 0.014) or in patients with the ITPase variant alone (n = 22) (P = 0.0095). The 6-TGN levels were significantly higher in patients with the MRP4 variant alone than in patients with the wild allelotype(P = 0.049). Of the 15 patients who experienced leucopenia (<3 x 10⁹/l), 7 patients carried the MRP4 variant.The odds ratio of carrying the MRP4 variant alone and having leukopenia was 3.30 (95% confidence interval 1.03–10.57, P = 0.036). CONCLUSIONS: These results suggest that MRP4 G2269A might be a new factor accounting for thiopurine sensitivity in Japanese patients with IBD.
Authors: Zuzana Zelinkova; Luc J J Derijks; Pieter C F Stokkers; Esther W M Vogels; Antoine H C van Kampen; Wouter L Curvers; Danny Cohn; Sander J H van Deventer; Daniël W Hommes Journal: Clin Gastroenterol Hepatol Date: 2006-01 Impact factor: 11.382
Authors: Partha Krishnamurthy; Matthias Schwab; Kazumasa Takenaka; Deepa Nachagari; Jessica Morgan; Mark Leslie; Weinan Du; Kelli Boyd; Meyling Cheok; Hiromitsu Nakauchi; Catia Marzolini; Richard B Kim; Balasubramanian Poonkuzhali; Erin Schuetz; William Evans; Mary Relling; John D Schuetz Journal: Cancer Res Date: 2008-07-01 Impact factor: 12.701
Authors: Xing-Xiang Peng; Zhi Shi; Vijaya L Damaraju; Xiao-Cong Huang; Gary D Kruh; Hsiang-Chun Wu; Ying Zhou; Amit Tiwari; Liwu Fu; Carol E Cass; Zhe-Sheng Chen Journal: Leuk Res Date: 2007-11-08 Impact factor: 3.156
Authors: Sukirti Kalra; Ying Zhang; Elena V Knatko; Stewart Finlayson; Masayuki Yamamoto; Albena T Dinkova-Kostova Journal: Cancer Prev Res (Phila) Date: 2011-07-29
Authors: Andrea Hahn; Tsuyoshi Fukuda; David Hahn; Tomoyuki Mizuno; Robert W Frenck; Alexander A Vinks Journal: Pharmacogenomics Date: 2016-04-05 Impact factor: 2.533
Authors: Chengcheng Liu; Laura J Janke; Jun J Yang; William E Evans; John D Schuetz; Mary V Relling Journal: Cancer Chemother Pharmacol Date: 2017-06-16 Impact factor: 3.333
Authors: Y Tanaka; A Manabe; H Fukushima; R Suzuki; H Nakadate; K Kondoh; K Nakamura; K Koh; T Fukushima; M Tsuchida; K Koike; N Kiyokawa; E Noguchi; R Sumazaki; T Komiyama Journal: Pharmacogenomics J Date: 2014-11-18 Impact factor: 3.550